Featured Publications Archives

← ALL PUBLICATIONS

Featured Publications

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Invivoscribe Marketing2024-05-02T11:47:00-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Invivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|

Leveraging Standardized MRD Assays to Guide CLL Treatment

wmm2024-01-25T10:44:11-08:00January 25th, 2024|2024 Publications, Featured Publications, Publications|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

wmm2023-04-10T20:22:16-07:00March 23rd, 2023|2023 Publications, Featured Publications, Publications|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

wmm2023-04-10T20:24:04-07:00March 2nd, 2023|2023 Publications, Featured Publications, Publications|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

wmm2022-12-29T21:22:21-08:00November 15th, 2022|2022 Publications, Featured Publications, Publications|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

wmm2022-12-29T21:19:31-08:00June 4th, 2022|2022 Publications, Featured Publications, Publications|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

wmm2023-01-08T18:20:36-08:00May 30th, 2022|2022 Publications, Featured Publications, Publications|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

Invivoscribe Marketing2022-09-07T22:22:23-07:00May 3rd, 2022|2022 Publications, Featured Publications, Publications|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

wmm2022-01-06T05:38:03-08:00January 4th, 2022|2022 Publications, Featured Publications, Publications|

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

Invivoscribe Marketing2022-09-07T22:31:04-07:00June 24th, 2021|2021 Publications, Featured Publications, Publications|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

wmm2023-01-10T16:48:18-08:00April 28th, 2021|2022 Publications, Featured Publications, Publications|

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Invivoscribe Marketing2021-02-17T18:10:07-08:00November 17th, 2020|2020 Publications, Featured Publications, Publications|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Invivoscribe Marketing2021-02-11T20:09:45-08:00October 13th, 2020|2020 Publications, Featured Publications, Publications|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2021-02-11T23:46:14-08:00March 21st, 2019|2019 Publications, Featured Publications, Publications|

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Invivoscribe Marketing2021-02-11T23:49:39-08:00August 25th, 2018|2018 Publications, Featured Publications, Publications|

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Invivoscribe Marketing2021-02-11T23:54:51-08:00August 22nd, 2018|2018 Publications, Featured Publications, Publications|

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

Invivoscribe Marketing2021-02-12T18:36:01-08:00October 31st, 2016|2016 Publications, Featured Publications, Publications|

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Leveraging Standardized MRD Assays to Guide CLL Treatment

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.